Alector (ALEC) Stock Overview
A clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ALEC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alector, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.12 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.87 |
| Beta | 0.55 |
| 1 Month Change | -3.20% |
| 3 Month Change | 46.21% |
| 1 Year Change | 59.40% |
| 3 Year Change | -65.13% |
| 5 Year Change | -89.40% |
| Change since IPO | -88.22% |
Recent News & Updates
Recent updates
Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key
Mar 11There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise
Jan 22
Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry
Sep 16This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year
Aug 13Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry
Jul 24US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results
May 11Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 05
ABC Platform And Latozinemab Trial Will Yield Mixed Prospects
Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%
Mar 21Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point
Mar 13Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts
Mar 01The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%
Dec 23Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates
Nov 28Alector: Bleak Prospects After Alzheimer's Failure
Nov 28Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry
Oct 24We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully
Sep 26Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking
Jul 11Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01Shareholder Returns
| ALEC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 0.4% | -1.6% |
| 1Y | 59.4% | 23.9% | 15.2% |
Return vs Industry: ALEC exceeded the US Biotechs industry which returned 25% over the past year.
Return vs Market: ALEC exceeded the US Market which returned 15.9% over the past year.
Price Volatility
| ALEC volatility | |
|---|---|
| ALEC Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ALEC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALEC's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 103 | Arnon Rosenthal | www.alector.com |
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
Alector, Inc. Fundamentals Summary
| ALEC fundamental statistics | |
|---|---|
| Market cap | US$239.49m |
| Earnings (TTM) | -US$142.93m |
| Revenue (TTM) | US$21.05m |
Is ALEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALEC income statement (TTM) | |
|---|---|
| Revenue | US$21.05m |
| Cost of Revenue | US$123.07m |
| Gross Profit | -US$102.02m |
| Other Expenses | US$40.91m |
| Earnings | -US$142.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | -484.77% |
| Net Profit Margin | -679.16% |
| Debt/Equity Ratio | 31.6% |
How did ALEC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 03:00 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alector, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |